Health Preference Research in Europe: A Review of Its Use in Marketing Authorization, Reimbursement, and Pricing Decisions - Report of the ISPOR Stated Preference Research Special Interest Group

Kevin Marsh*, Janine A. van Til, Elizabeth Molsen-David, Christine Juhnke, Natalia Hawken, Elisabeth M. Oehrlein, Y. Christy Choi, Alejandra Duenas, Wolfgang Greiner, Kara Haas, Mickael Hiligsmann, Kimberley S. Hockley, Ilja Ivlev, Frank Liu, Jan Ostermann, Thomas Poder, Jiat L. Poon, Axel Muehlbacher

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Scopus)

Abstract

Objective: This study examines European decision makers' consideration and use of quantitative preference data.

Methods: The study reviewed quantitative preference data usage in 31 European countries to support marketing authorization, reimbursement, or pricing decisions. Use was defined as: agency guidance on preference data use, sponsor submission of preference data, or decision-maker collection of preference data. The data could be collected from any stakeholder using any method that generated quantitative estimates of preferences. Data were collected through: (1) documentary evidence identified through a literature and regulatory websites review, and via key opinion leader outreach; and (2) a survey of staff working for agencies that support or make healthcare technology decisions.

Results: Preference data utilization was identified in 22 countries and at a European level. The most prevalent use (19 countries) was citizen preferences, collected using time-trade off or standard gamble methods to inform health state utility estimation. Preference data was also used to: (1) value other impact on patients, (2) incorporate non-health factors into reimbursement decisions, and (3) estimate opportunity cost. Pilot projects were identified (6 countries and at a European level), with a focus on multi-criteria decision analysis methods and choice-based methods to elicit patient preferences.

Conclusion: While quantitative preference data support reimbursement and pricing decisions in most European countries, there was no utilization evidence in European-level marketing authorization decisions. While there are commonalities, a diversity of usage was identified between jurisdictions. Pilots suggest the potential for greater use of preference data, and for alignment between decision makers.

Original languageEnglish
Pages (from-to)831-841
Number of pages11
JournalValue in health
Volume23
Issue number7
Early online date5 Jul 2020
DOIs
Publication statusPublished - Jul 2020

Keywords

  • Benefit-risk assessment
  • European regulatory
  • Health preferences
  • Health technology assessment
  • Marketing authorization
  • Preference research
  • Pricing
  • Quantitative preference data
  • Reimbursement
  • Stakeholder preferences

Fingerprint Dive into the research topics of 'Health Preference Research in Europe: A Review of Its Use in Marketing Authorization, Reimbursement, and Pricing Decisions - Report of the ISPOR Stated Preference Research Special Interest Group'. Together they form a unique fingerprint.

Cite this